Abstract 284P
Background
Head and neck squamous cell carcinoma (HNSCC) was the 8th most common cancer worldwide in 2018. Incidence and mortality rates of HNSCC vary by geographical location, and Taiwan has one of the world’s highest incidence rates of oral cancers. Metronomic chemotherapy inhibits tumor growth by continuous administration of lower-dose chemotherapy. Our study aims to demonstrate the outcomes of metronomic chemotherapy with tegafur-uracil (UFUR) in locally advanced HNSCC.
Methods
This is a retrospective study. We included 240 patients with locally advanced (stage III or non-distant metastatic stage IV) HNSCC. Operable patients without post-operational high-risk features were excluded. High-risk features were positive surgical margins, extranodal extension (ENE), perineural invasion (PNI) or lymphovascular invasion (LVI). After standard treatment, 96 patients were further treated with metronomic UFUR and 144 patients were not. The last date of follow-up of this study was 5 April 2020.
Results
There were also no statistical differences between both groups in gender, clinical cancer stage and primary treatment choice. However, there were more hypopharynx cancers in UFUR group and more oral cavity cancers in control group. There were significantly more high-grade features, including LVI (P=0.018), ENE (P<0.001), and positive margin (P=0.025) in UFUR group. The median follow-up duration was 31.16 months (range: 3.80-87.38). The overall survival was not reached in the UFUR group and 54.1 months in control group (p =0.008). For disease-free survival (DFS), the median DFS was 54.5 months (95% CI=40.7-not reached) in the UFUR group and 34.4 months (95% CI=25.2-not reached) in the control group (p =0.03). For distant metastasis-free survival, both groups were not reached (p =0.02). In both groups, primary local recurrence was the most common reason of treatment failure. Overall prevalence of adverse event of UFUR was very low and the most common adverse events were low-grade nausea (3.8%), vomiting (3.3%), neutropenia (1.7%) and mucositis (2.1%).
Conclusions
In patients with high-risk and unresectable locally advanced HNSCC, adding UFUR as a metronomic chemotherapy after either curative surgery with adjuvant chemoradiotherapy or definitive concurrent chemoradiotherapy was found to significantly improve OS, DFS and DMFS rates with tolerable adverse events.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
413P - South Korean real-world treatment patterns in patients with EGFRm NSCLC
Presenter: Jae Cheol Lee
Session: e-Poster Display Session
414P - Incidence and characteristics of lung cancer diagnosed after kidney transplantation at the National Kidney and Transplant Institute
Presenter: Adeline Gonzales
Session: e-Poster Display Session
415P - Real-world fusion landscape of RET gene fusions and its response to cabozantinib in Chinese non-small cell lung cancer (NSCLC) using next generation sequencing
Presenter: Chunwei Xu
Session: e-Poster Display Session
416P - A single institute study evaluating the additional benefit of blood NGS testing over conventional molecular testing in metastatic adenocarcinoma lung
Presenter: Rajashree Ashwath
Session: e-Poster Display Session
417P - Efficacy and safety of lorlatinib in subsequent lines of therapy in ALK and ROS1 positive lung cancer
Presenter: Amit Kumar
Session: e-Poster Display Session
418P - All EGFR mutations are (not) created equal: Focus on uncommon EGFR mutations
Presenter: Ullas Batra
Session: e-Poster Display Session
419P - Surgical treatment of malignant tumours and metastatic lesions of the chest wall
Presenter: Zhanat Pyssanova
Session: e-Poster Display Session
421P - A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China
Presenter: Ming Gao
Session: e-Poster Display Session
422P - Response rate and time to progression after first line chemotherapy with cisplatin and adriamycin in patients with metastatic osteosarcoma at presentation
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
423P - Positive lymph node and thicker Breslow are associated with poor prognosis of high-risk resected melanomas
Presenter: Roby Cahyono
Session: e-Poster Display Session